RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19 (MACH19)
Multicenter Double Blind, Placebo Controlled RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19
Sponsor: Gordon Saxe
This PHASE1/PHASE2 trial investigates COVID-19 and is currently completed. Gordon Saxe leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
Dec 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2022 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gordon Saxe
- University of California, Irvine
- University of California, Los Angeles
For direct contact, visit the study record on ClinicalTrials.gov .